Stereotaxis
NYSE STXS · St.Louis, MO
Works in Cardiovascular · Genetic & rare
Stereotaxis is a clinical trial sponsor based in St.Louis, MO, listed as NYSE STXS. It has 2 active clinical trials with 190 planned participants, in Cardiovascular and Genetic & rare. Since 2021 it has completed 1 trial and stopped 1 early.
Trial track record · since 2021
Financials · NYSE STXS
Fundraising
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Stereotaxis
Stereotaxis is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 190 planned participants, in Cardiovascular, Genetic & rare. Since 2021 it has completed 1 trial and stopped 1 early.
Stereotaxis is based in St.Louis, MO and is listed as NYSE STXS. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Stereotaxis; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-10.
Approve Suite is not affiliated with Stereotaxis. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.